The FDA’s Stance on Hemp-Derived CBD as a Dietary Supplement (Part 2)

美国FDA对大麻CBD作为膳食补充剂的立场(第二部分)

2019-07-22 18:23:00 cannalawblog

本文共2679个字,阅读需7分钟

This is the second installment in our series on the Food and Drug Administration (“FDA”) and hemp-derived CBD (“Hemp-CBD”). Our last post focused on the Drug Exclusion Rule, which essentially states that an article cannot be marketed as a dietary supplement if it was investigated or approved as a drug before the article was marketed as a dietary supplement (or food). Today, we’ll take a look at what that use of “before” really means. Prior Market Clause A key component of the Drug Exclusion Rule is that the article at issue was not previously marketed before the article was evaluated or approved by the FDA (the “Prior Market Clause”). So what does it mean to “market” a product? Helpfully, the FDA FAQs link to Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues (“NDI Guidance”) to provide an explanation of the phrase “marketed as.” The NDI Guidance, which like the FDA FAQs is nonbinding, elaborates on the idea of “marketing”: “FDA considers ‘marketing’ a dietary ingredient to mean selling or offering the dietary ingredient for sale (1) as or in a dietary supplement, (2) in bulk as a dietary ingredient for use in dietary supplements, or (3) as an ingredient in a blend or formulation of dietary ingredients for use in dietary supplements. A dietary ingredient may be “marketed” by offering the article for sale online or at a retail establishment, listing it for sale in a catalog or price list, or through advertising or other promotion, if the promotion makes clear that the article is available for purchase. ‘Coming soon’ advertisements would not qualify.” The NDI Guidance goes on to state “[i]n considering whether a substance has been ‘marketed as a dietary supplement or as a food,’ FDA looks for evidence of one of the following: “1. Evidence that the substance itself was sold or offered for sale in the U.S. as a dietary supplement, dietary ingredient for use in dietary supplements, or conventional food. For example, a catalog listing a product identified as a ‘Substance A supplement’ would establish the marketing of Substance A as a dietary supplement. Similarly, business records documenting that a substance was sold or offered for wholesale or retail sale for use as an ingredient in a conventional food would establish the marketing of the substance as a food. 2. Evidence that the substance was a component of a food or dietary supplement that was sold or offered for sale in the U.S., and that a manufacturer or distributor of the food or dietary supplement marketed it for the content of the substance by, for example, making claims about the substance or otherwise highlighting its presence in the product. For example, in Pharmanex v. Shalala, the firm marketed lovastatin, a component of its red yeast rice product Cholestin, by promoting the lovastatin content of Cholestin. Merely showing that the substance was present as a component in a marketed food would not be enough to show that the substance was ‘marketed,’ however.” Red Yeast Rice The NDI Guidance’s reference to Pharmanex v. Shalala is of note as that case may have a major bearing on Hemp-CBD. Back in April 1997, the FDA issued a warning letter to Pharmanex, stating that it was selling a drug as a dietary supplement. Pharmanex manufactured Cholestin, a dietary supplement derived from red yeast rice intended to promote healthy cholesterol levels. Cholestin contained the substance mevinolin. Mevinolin was chemically identical to lovastatin, the active ingredient in the prescription drug Mevacor. The FDA approved Mevacor back in 1987. The FDA advised Pharmanex that it considered Cholestin to be a drug which could not be marketed without FDA approval. Pharmanex argued that red yeast rice had been used a food ingredient for thousands of years. The FDA was not convinced, ultimately holding that Cholestin containing lovastatin did not meet the definition of a “dietary supplement” because lovastatin was an “article” that had already been approved as a drug. The FDA determined that Cholestin did not satisfy the Prior Marketing Clause because it did not contain red yeast rice as that product had traditionally been manufactured and marketed. The FDA ran tests on samples of red yeast rice and found small amounts of lovastatin. In the FDA’s view, Pharmanex had manipulated red yeast rice to increase the lovastatin content and therefore the Drug Exclusion Rule applied. Pharmanex challenged the FDA’s ruling in district court. The district court set aside the FDA’s decision, agreeing with Pharmanex that the term “article” as used in the FDCA did not refer to a single ingredient in a drug. The Court of Appeals for the Tenth Circuit reversed, holding that “article” could include the active ingredients of approved new drugs, such as lovastatin, which would exclude them from the dietary supplement definition. On remand, the district court affirmed the FDA’s original conclusion that lovastatin was not marketed as a dietary supplement or food before the FDA approved Mevacor as a prescription drug. Cholestin containing lovastatin is no longer on the market in the US. There are still red yeast rice supplements available but the FDA monitors whether those supplements contain more than the naturally occurring amount of lovastatin. The Future of Hemp-CBD The Pharmanex case could dictate how the FDA treats Hemp-CBD. Hemp contains many active compounds, including cannabinoids like CBD and terpenes. Hemp can be processed in a number of ways, some of which will isolate these active compounds. Chemical extraction methods can isolate these active compounds while removing water, fiber, and other unwanted material. Alternatively, hemp can be processed without the use of chemicals (e.g., dried flowers; chopped up plant material placed in pellets, etc.). “Full spectrum” extracts are the extracts that contain a wide array of compounds found in the hemp plant, including cannabinoids and terpenes. Processors can also isolate specific compounds by repeatedly extracting and refining the compound. Epidiolex is an example of a CBD isolate. A CBD isolate generally contains almost no other compounds. In turn, full spectrum extracts contain trace amounts of CBD and their compounds. Following the reasoning in Pharmanex, CBD isolate may be subject to the Drug Exclusion Rule, but processed hemp, including full spectrum extracts may not due to the Prior Marketing Clause. This is because like Red Yeast Rice, hemp has been consumed as food and medicine for thousands of years. Hemp is not the same as the CBD isolate. The Pharmanex case turned on the an interpretation of the term “article.” CBD isolate is the article that was approved as a drug. Full spectrum extracts and other processed hemp products that contain naturally occurring CBD also may be outside of the scope of the Drug Exclusion Rule by way of Epidiolex. In turn, CBD isolate or processed hemp that had isolated and increased CBD could only legally be sold as drugs. Though the parallel between Hemp-CBD and red yeast rice are impossible to ignore, there is no gaurantee that the FDA will take the same exact approach. For one, perhaps it can be established that CBD, in its isolated form was marketed prior to the Epidiolex studies being made public. CBD was first discovered by Dr. Roger Adams at the University of Illinois in 1940. However, any marketing of CBD isolate prior to the first Epidiolex investigations in 2014, would have likely violated federal law because the 2014 Farm Bill was not yet in effect, making it illegal under federal law. However the FDA’s statement following the 2018 Farm Bill included some very interesting language: ”[P]athways remain available for the FDA to consider whether there are circumstances in which certain cannabis-derived compounds might be permitted in a food or dietary supplement. Although such products are generally prohibited to be introduced in interstate commerce, the FDA has authority to issue a regulation allowing the use of a pharmaceutical ingredient in a food or dietary supplement. We are taking new steps to evaluate whether we should pursue such a process.” The FDA Secretary can override the Drug Exclusion Rule by issuing “a regulation, after notice and comment, finding that the article would be lawful under [the FDCA].” The statement also went onto ask for input on the future of Hemp-CBD: “Given the substantial public interest in this topic and the clear interest of Congress in fostering the development of appropriate hemp products, we intend to hold a public meeting in the near future for stakeholders to share their experiences and challenges with these products, including information and views related to the safety of such products.” We will continue to monitor the FDA for additional updates on Hemp-CBD.
这是我们关于食品和药物管理局(FDA)和大麻衍生CBD(大麻CBD)系列文章的第二部分。我们的上一篇文章关注的是药物排除规则,该规则基本上规定,如果一种物质在作为膳食补充剂(或食品)销售之前就被调查或批准为药物,那么它就不能作为膳食补充剂销售。今天,我们来看看“before”的真正含义。 之前的市场条款 药物排除规则的一个关键组成部分是,在该产品被FDA评估或批准之前(先前的市场条款),有争议的产品并未上市。那么,营销一种产品意味着什么呢?有益的是,FDA faq链接到行业指南草案:膳食补充剂:新的膳食成分通知和相关问题(NDI指南),以提供一个短语的解释营销为。 与FDA常见问题一样,NDI指南也没有约束力,它详细阐述了营销的概念: ”FDA认为营销膳食成分意味着出售或提供出售的膳食因素或膳食补充剂(1),(2)散装膳食成分用于膳食补充剂,或(3)在混合或制定膳食成分用于膳食补充剂。一种膳食成分可以通过在网上或零售场所出售该物品、在目录或价格表中列出出售该物品、或者通过广告或其他促销手段进行营销,如果促销手段表明该物品可供购买的话。即将到来的广告将没有资格。“ NDI指南继续陈述[i]n考虑到一种物质是作为膳食补充剂还是作为食品销售,FDA寻找下列证据之一: 1. 证明该物质本身作为膳食补充剂、膳食补充剂中的膳食成分或传统食品在美国出售或出售的证据。例如,将一种产品列为a物质补充剂的目录将建立a物质作为膳食补充剂的营销。同样,记录一种物质作为一种传统食品的一种成分被出售或提供给批发或零售的商业记录将确立这种物质作为一种食品的销售。 2. 有证据表明,这种物质是在美国出售或出售的食品或膳食补充剂的成分,以及食品或膳食补充剂的生产商或分销商就该物质的含量进行营销,例如,对该物质作出声明或以其他方式强调其在产品中的存在。例如,在Pharmanex v. Shalala一案中,该公司通过提高洛伐他汀的胆石含量来推销其红曲米产品胆石的成分洛伐他汀。然而,仅仅表明这种物质作为一种成分存在于已上市的食品中,并不足以表明这种物质已上市。 红曲米 值得注意的是,NDI指南中提到的Pharmanex v. Shalala一案可能对大麻cbd产生重大影响。早在1997年4月,FDA就向Pharmanex发出了一封警告信,声明其正在销售一种作为膳食补充剂的药物。Pharmanex公司生产胆石,一种从红曲米中提取的膳食补充剂,旨在促进健康的胆固醇水平。胆石中含有mevinolin物质。Mevinolin的化学成分与处方药Mevacor中的活性成分洛伐他汀相同。FDA早在1987年就批准了Mevacor。FDA建议Pharmanex认为胆石是一种未经FDA批准不能上市的药物。Pharmanex公司认为红曲米作为一种食品原料已经有几千年的历史了。FDA并不相信,最终认为含有洛伐他汀的胆石不符合膳食补充剂的定义因为洛伐他汀是一种已经被批准为药物的药物。FDA认定胆石不符合先前的销售条款,因为它不包含传统上生产和销售的红曲米。FDA对红曲米样品进行了检测,发现了少量洛伐他汀。FDA认为,Pharmanex公司操纵红曲米,以增加洛伐他汀的含量,因此适用药物排除规则。 Pharmanex公司在地区法院对FDA的裁决提出质疑。地方法院驳回了FDA的决定,同意Pharmanex的观点,即FDCA中使用的术语article并不是指药物中的单一成分。第十巡回上诉法院推翻了这一观点,认为该条款可以包括已获批准的新药的活性成分,如洛伐他汀,这将把它们排除在膳食补充剂的定义之外。在remand案中,地区法院确认了FDA最初的结论,即在FDA批准Mevacor作为处方药之前,洛伐他汀并没有作为膳食补充剂或食品销售。 含有洛伐他汀的胆石已不在美国市场上销售。目前仍有红曲米补充剂,但FDA会监控这些补充剂中是否含有超过自然含量的洛伐他汀。 大麻cbd的未来 Pharmanex的案例可能会决定FDA如何对待大麻cbd。大麻含有许多活性化合物,包括大麻素,如CBD和萜烯。大麻可以用多种方法加工,其中一些方法可以分离出这些活性化合物。化学萃取法可以分离这些活性化合物,同时去除水、纤维和其他不需要的物质。此外,大麻可以在不使用化学品的情况下加工(例如,干花;切碎的植物材料放入球团等)。 全谱萃取物是大麻植物中含有多种化合物的萃取物,包括大麻素和萜烯。处理器还可以通过重复提取和精炼化合物来分离特定的化合物。附睾酮是CBD分离物的一个例子。CBD分离物通常几乎不含其他化合物。全谱萃取物中含有微量的CBD及其化合物。 按照Pharmanex的推理,CBD分离物可能受药物排除规则的约束,但加工过的大麻,包括全谱萃取物可能不受先前营销条款的限制。这是因为就像红曲米一样,大麻作为食物和药物已经有几千年的历史了。大麻是不一样的CBD隔离。法马尼克斯一案涉及对条款一词的解释。CBD分离物是被批准作为药物的文章。全谱提取物和其他含有天然CBD的加工大麻制品也可能通过附睾酮的方式超出药物排除规则的范围。反过来,CBD分离物或已分离并增加CBD的加工大麻只能合法地作为药物出售。 尽管大麻二酚和红曲米的相似之处不容忽视,但并不能保证FDA也会采取同样的方法。首先,也许可以确定CBD,在Epidiolex研究公开之前,其孤立的形式就已经上市了。CBD最早是由伊利诺斯大学的罗杰·亚当斯博士于1940年发现的。然而,在2014年Epidiolex进行第一次调查之前,任何CBD的销售都有可能违反联邦法律,因为2014年的农业法案还没有生效,根据联邦法律,这是非法的。 然而,FDA在2018年农业法案之后的声明中包含了一些非常有趣的语言: “FDA仍然可以考虑在某些情况下是否允许在食品或膳食补充剂中添加某些大麻衍生化合物。尽管此类产品一般禁止在州际贸易中引入,但FDA有权发布一项法规,允许在食品或膳食补充剂中使用药物成分。我们正在采取新的步骤来评估我们是否应该进行这一进程。” 美国食品药品监督管理局局长可以通过发布一项规定,推翻药物排除规则,在通知和评论之后,发现该条款在[FDCA]下是合法的。声明还就大麻cbd的未来征求意见: “鉴于这一主题重大公共利益和国会的明确利益促进适当的麻产品的发展,我们打算举行一次公开会议在不久的将来为利益相关者分享他们的经验和挑战这些产品,包括信息和观点有关此类产品的安全。” 我们将继续监测FDA关于大麻cbd的额外更新。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文